Jiangsu Hengrui Pharmaceuticals: Authorized revenue becomes the "accelerator" for performance.

Personnel, products, and research and development are gradually becoming Global.

wallstreetcnApr 24 07:29 ET

The upfront payment for the new ADC drug has boosted revenue, Jiangsu Hengrui Pharmaceuticals' Q1 revenue increased by 20.14% year-on-year, and net income increased by 36.9% | Earnings Reports insights.

In Q1, Jiangsu Hengrui Pharmaceuticals' revenue increased by 20.14% year-on-year, net income attributable to the parent company increased by 36.9%, and net income after deductions increased by 29.35% year-on-year. The significant increase in net income was primarily due to the company receiving a $75 million upfront payment for external licensing.

wallstreetcnApr 24 06:03 ET

Fumetinib drives performance growth, Shanghai Allist Pharmaceuticals Co., Ltd. expects net profit to increase by over 120% year-on-year in 2024.

① During the reporting period, Shanghai Allist Pharmaceuticals Co., Ltd. achieved revenue of 3.558 billion yuan, a year-on-year increase of 76.29%; net income attributable to shareholders was 1.43 billion yuan, up 121.97% year-on-year, and net income excluding extraordinary items was 1.361 billion yuan, an increase of 124.51% year-on-year; ② The net cash flow reached 1.566 billion yuan, a growth of 132.12% compared to 0.675 billion yuan in the same period last year. Ample funds are beneficial for expanding R&D investment.

cls.cnApr 24 00:28 ET

Limit up during the day and a warning at night? JiangSu WuZhong Pharmaceutical Development's annual report may receive an audit report with an inability to express an opinion | Quick read of the announcement.

① Due to various reasons such as overdue accounts receivable and receivables overdue in the trade business, JiangSu WuZhong Pharmaceutical Development does not rule out the possibility of receiving an audit report expressing an inability to issue an opinion in the 2024 report. ② In addition to being investigated for violations of information disclosure and multiple Bearish factors, JiangSu WuZhong is currently in a precarious situation.

cls.cnApr 23 11:59 ET

In 2024, Shanghai Yizhong's Net income decreased sharply by 95.68% year-on-year. Core products are included in medical insurance, but performance is under pressure.

① Despite the successful inclusion of core products in the national medical insurance directory, due to factors such as market access difficulties and increased R&D investment, Shanghai Yizhong's revenue and Net income are expected to decline significantly in 2024; ② Shanghai Yizhong stated that it will continue to promote the expansion of indications and the construction of marketing networks to break through market bottlenecks.

cls.cnApr 22 10:57 ET

Is the major source of revenue for PKU HealthCare Corp. lost or acquired by a 'mystery buyer,' revealing symptoms of an 'aftershock'? | Quick read of the announcement.

① Related revenue accounts for nearly one third of PKU HealthCare Corp.'s revenue, and the Net income is almost completely covered; ② Last December, after being acquired by mysterious investor Xu Xiren from Zhejiang, PKU HealthCare Corp. needs to separate from the "Peking University" brand; ③ Since the acquisition occurred, PKU HealthCare Corp.'s Market Cap has shrunk by nearly one fifth.

cls.cnApr 22 06:43 ET